

PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Juvenile Idiopathic Arthritis (OAA)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

	I		
	Prescriber Name:		
Patient Name:	Supervising Physician:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:		
Primary Phone:	Specialty/facility name	(if applicable):	
Drug Name and Strength:			
Directions / SIG:			
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.			
Q1. What drug is being requested?			
£ Actemra (tocilizumab) - IV Formulation			
\pounds Enbrel (etanercept)			
£ Humira (adalimumab)			
${\mathfrak L}$ Orencia (abatacept)- IV Formulation			
Q2. What diagnosis is this drug being prescribed for (pick of	one)?		
£ POLYARTICULAR juvenile idiopathic arthritis (JIA) [proceed to Q3-7]			
£ SYSTEMIC juvenile idiopathic arthritis (JIA) [proceed to Q3-4, 8]			
£ Other			
Q3. Please provide ICD code(s) for diagnosis.			
Q4. Is the prescriber a Rheumatologist?			
£ Yes £ No			
Q5. If the diagnosis is POLYARTICULAR JIA, has the patie methotrexate, sulfasalazine, or leflunomide?	ent failed or does the p	atient have a contraindication to	
£ Yes £ No			



PRIOR AUTHORIZATION REQUEST FORM EOC ID: Juvenile Idiopathic Arthritis (OAA)

Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Phone: 800-728-7947

		Prescriber Name:
Patient Name:		Supervising Physician:
Q6. If the diagnosis	is POLYARTICULAR JIA, ha	s the patient failed another anti-TNF agent?
\pounds Yes	£ No	
•	gnosis is POLYARTICULAR J Enbrel or Humira?	IIA, and the request is for ACTEMRA – IV or ORENCIA – IV, has the
\pounds Yes	£ No	
Q8. If diagnosis is S glucocorticoids, or h	•	nt failed or does the patient have a contraindication to NSAIDs,
£ Yes	£ No	
Q9. Additional Com	ments	
	Prescriber Signature	Date
		ning above, I certify that applying the standard review timeframe may
seriously jeopardize	the life or health of the enrolle	ee or the enrollee's ability to regain maximum function
Lack of the necessary	documentation may result in a mo	edical necessity denial. Requesting providers may speak to the SWHP medical
		an opportunity to help impact the decision on a request before coverage has been

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

decided.